We are excited to present that Biocytogen will be attending the 61st (EASD) European Association for the Study of Diabetes Annual Meeting from September 15th-19th in Vienna, Austria! Join us for a week of exciting opportunities to interact with colleagues around the world for eye-opening discussions for detection and in-depth research for diabetes. Visit booth #E2.09 and meet our talented members and learn how Biocytogen is accelerating the development of next-generation research on diabetes. We look forward to connecting with you and exploring new opportunities together!
What is the EASD Annual Meeting?
Created in 2000, the EASD( European Association for the Study of Diabetes) is an academic non-profit that commits to diabetes research in Europe, and has dedicated over 100 million euros to this project and is constantly striving to create awareness around the world to address the severity and magnitude of the disease. The 61st annual meeting is held this September with symposiums, special events, lab talks and social time to fully connect with professionals across countries and fields.
Event Overview
Date: September 15th- September 19th
Venue: VIECON - Vienna Congress & Convention Center (Messe Vienna) Messeplatz 1, 1021 Vienna, Austria
Event Schedule
For more event information, please refer to EASD Meeting Schedule
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you in Vienna!
